{"id":9135,"date":"2025-11-03T11:08:33","date_gmt":"2025-11-03T08:08:33","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9135"},"modified":"2025-11-03T11:08:33","modified_gmt":"2025-11-03T08:08:33","slug":"dr-feras-bader-advanced-heart-failure-and-transplant-a-regional-perspective","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/dr-feras-bader-advanced-heart-failure-and-transplant-a-regional-perspective\/","title":{"rendered":"Dr. Feras Bader \u2013 \u201cAdvanced Heart Failure and Transplant: A Regional Perspective\u201d"},"content":{"rendered":"<div>Dr. Feras Bader \u2013 \u201cAdvanced Heart Failure and Transplant: A Regional Perspective\u201d<\/div>\n<div><\/div>\n<div>JCS Conference | 16 October 2025<\/div>\n<div><\/div>\n<div>Keynotes:<\/div>\n<div>1. Global Overview<\/div>\n<div><span> 1. Heart failure (HF) affects about 2 % of adults worldwide, with 1-year mortality 15\u201330 %.<\/span><\/div>\n<div><span> 2. Around one in four people will develop HF during their lifetime.<\/span><\/div>\n<div><span> 3. Despite advances, the 5-year survival for all HF types remains only about 20\u201325 %.<\/span><\/div>\n<div><\/div>\n<div>2. Regional &amp; Asian Burden<\/div>\n<div><span> 4. HF prevalence is rising across Asia, mainly due to ischemic and hypertensive heart disease.<\/span><\/div>\n<div><span> 5. Top 3 countries (2019): China, Kuwait, and Jordan.<\/span><\/div>\n<div><span> 6. The Eastern Mediterranean Region (EMR) continues to show a steady increase in HF cases.<\/span><\/div>\n<div>(EMR includes Jordan, Saudi Arabia, UAE, Kuwait, Qatar, Lebanon, Egypt, etc.)<\/div>\n<div><\/div>\n<div>3. Advanced HF (AHF) Burden<\/div>\n<div><span> 7. AHF = Advanced Heart Failure (NYHA III\u2013IV), representing severe functional limitation.<\/span><\/div>\n<div><span> 8. From 1990\u20132019: global AHF rates fell by 7 %, but increased by 8 % in the EMR.<\/span><\/div>\n<div><span> 9. 2019: ~1.23 million EMR patients lived with AHF (60 % male), causing ~180,000 years lived with disability (YLDs).<\/span><\/div>\n<div><span> 10. 2021: ~1.12 million AHF cases (+6 % vs 1990) and ~195,000 YLDs (+7 %), meaning more patients live longer but with serious symptoms.<\/span><\/div>\n<div><\/div>\n<div>4. Country Trends<\/div>\n<div><span> 11. Highest AHF prevalence: Kuwait, Qatar, UAE.<\/span><\/div>\n<div><span> 12. Fastest growth: Oman, Bahrain, UAE, Saudi Arabia, Qatar.<\/span><\/div>\n<div><span> 13. Calls for early detection, prevention, and specialized multidisciplinary HF care.<\/span><\/div>\n<div><\/div>\n<div>5. Historical Milestones<\/div>\n<div><span> 14. First heart transplant (HTx): Jordan 1985 \u2192 Saudi Arabia 1986 \u2192 Syria 1989 \u2192 Iran 1993 \u2192 Tunisia 1993 \u2192 Lebanon 1997 \u2192 UAE 2017 \u2192 Kuwait 2019.<\/span><\/div>\n<div><span> 15. MCS (Mechanical Circulatory Support): devices that help the heart pump blood \u2014 first used in Saudi Arabia (2003), then Qatar (2008), Lebanon (2009), and UAE (2017).<\/span><\/div>\n<div><\/div>\n<div>6. AHF Therapy Availability<\/div>\n<div><span> 16. Only 27 % of EMR countries offer both LVAD (Left Ventricular Assist Device) and heart transplant programs.<\/span><\/div>\n<div><span> 17. LVAD use: 55 % as destination therapy, 33 % as bridge-to-transplant, 11 % for recovery.<\/span><\/div>\n<div><span> 18. About half of EMR countries refer patients abroad for AHF therapy; around 40 % provide full government coverage.<\/span><\/div>\n<div><\/div>\n<div>7. Transplant &amp; Organ Donation<\/div>\n<div><span> 19. Deceased-donor programs remain limited but are slowly expanding.<\/span><\/div>\n<div><span> 20. UAE program (2017\u20132025): 38 heart transplants, mostly Emiratis (68 %), with 1-year survival around 89.5 %.<\/span><\/div>\n<div><span> 21. Regional transplant referrals occur between UAE, Kuwait, Saudi Arabia, Lebanon, Jordan, Iraq, Pakistan, and India \u2014 reflecting collaboration but also the need for more local programs.<\/span><\/div>\n<div><\/div>\n<div>8. Multidisciplinary Care<\/div>\n<div><span> 22. Best outcomes come from team-based HF programs involving cardiologists, surgeons, nurses, and rehab specialists.<\/span><\/div>\n<div><span> 23. Cleveland Clinic Abu Dhabi\u2019s model improved guideline therapy use, reduced hospital stay, and lowered mortality.<\/span><\/div>\n<div><\/div>\n<div>9. Future Vision<\/div>\n<div><span> 24. More regional HF and transplant centers are expected.<\/span><\/div>\n<div><span> 25. Early referrals and organized evaluation systems are essential to reduce urgent transplants.<\/span><\/div>\n<div><span> 26. National donor registries and cross-country coordination will improve organ use and patient outcomes.<\/span><\/div>\n<div><\/div>\n<div>10. Key Takeaways<\/div>\n<div><span> 27. HF burden is increasing globally and in the EMR.<\/span><\/div>\n<div><span> 28. Costs are rising; stronger regional cooperation is needed.<\/span><\/div>\n<div><span> 29. Effective care begins and ends with a multidisciplinary HF team<\/span><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Feras Bader \u2013 \u201cAdvanced Heart Failure and Transplant: A Regional Perspective\u201d JCS Conference | 16 October 2025 Keynotes: 1. Global Overview 1. Heart failure (HF) affects about 2 % of adults worldwide, with 1-year mortality 15\u201330 %. 2. Around one in four people will develop HF during their lifetime. 3. Despite advances, the 5-year [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9135","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9135"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9135\/revisions"}],"predecessor-version":[{"id":9136,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9135\/revisions\/9136"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}